Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I), among other approved uses. It is available as tablets, kits and powder for injection for oral and intravenous use. MedsAcross supplies Selexipag for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.
Source: US FDA prescribing information
Selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin. Selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag. Selexipag and the active metabolite are selective for the IP receptor versus other prostanoid receptors (EP 1–4, DP, FP, and TP).
Source: US FDA prescribing information
Adult patients: UPTRAVI tablets starting dose: 200 mcg orally twice daily. Increase the dose by 200 mcg orally twice daily at weekly intervals to the highest tolerated dose up to 1,600 mcg orally twice daily. Pediatric patients: See Full Prescribing Information for recommended starting dose, titration increments, and maximum allowed dose based on body weight category. Maintenance dose is determined by tolerability. Moderate hepatic impairment: Starting dose once daily, increase in increments of the starting dose once daily at weekly intervals to the maximum allowed or highest tolerated dose. Adult patients: UPTRAVI for injection dose is determined by the patient's current dose of UPTRAVI tablets. Administer UPTRAVI for injection by intravenous infusion, twice daily. See Full Prescribing Information for instructions on preparation and administration.
Source: US FDA prescribing information
Hypersensitivity to the active substance or to any of the excipients. Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil). Concomitant use with strong CYP2C8 inhibitors.
Source: US FDA prescribing information
Pulmonary edema in patients with pulmonary veno-occlusive disease. If confirmed, discontinue treatment. Pulmonary Edema with Pulmonary Veno-Occlusive Disease Should signs of pulmonary edema occur, consider the possibility of associated pulmonary veno-occlusive disease. If confirmed, discontinue UPTRAVI.
Source: US FDA prescribing information
Adverse reactions in adult and pediatric patients occurring more frequently (≥5%) on UPTRAVI compared to placebo are headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing. Additional adverse reaction occurring in pediatric patients more frequently (≥5%) on UPTRAVI compared to placebo is abdominal pain.
Source: US FDA prescribing information
Moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide) increase exposure to the active metabolite of UPTRAVI. Reduce the dosing of UPTRAVI to once daily. CYP2C8 inducers (e.g., rifampin) decrease exposure to the active metabolite. Increase up to twice the dose of UPTRAVI.
Source: US FDA prescribing information
Store at 20 °C to 25 °C (68 °F to 77 °F). Excursions are permitted between 15 °C and 30 °C (59 °F and 86 °F). Storage conditions for UPTRAVI for injection: Store the original carton containing glass vial in a refrigerator at 2 °C to 8 °C (36 ºF to 46 ºF) until use in order to protect from light. Recommended storage for UPTRAVI 100 mcg and 150 mcg tablets: Store and dispense in the original package to protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
20 presentations of Selexipag, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Selexipag 200 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Selexipag 1000 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Selexipag 1200 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Selexipag 1400 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Selexipag 1600 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Selexipag 400 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Selexipag 600 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Selexipag 800 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Uptravi 200 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 100 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 1000 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 1200 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 1400 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 150 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 1600 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 1800 mcg/10 mL powder for injectionIntravenous Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 400 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 600 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| Uptravi 800 mcg tabletOral Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
| UPTRAVI Titration Pack kit Cold chain | Actelion Pharmaceuticals | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Selexipag in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 20 presentations of Selexipag and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Selexipag, including Uptravi, UPTRAVI Titration Pack.
Yes. The US FDA first approved Selexipag on 21 December 2015, according to Drugs@FDA.
Yes. Selexipag has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Selexipag must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Selexipag is classified under ATC code B01AC27 (Selexipag).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.